CA2876529C - Method for treating a gd2 positive cancer - Google Patents
Method for treating a gd2 positive cancer Download PDFInfo
- Publication number
- CA2876529C CA2876529C CA2876529A CA2876529A CA2876529C CA 2876529 C CA2876529 C CA 2876529C CA 2876529 A CA2876529 A CA 2876529A CA 2876529 A CA2876529 A CA 2876529A CA 2876529 C CA2876529 C CA 2876529C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- treatment
- dose
- day
- morphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/061618 | 2012-06-18 | ||
| PCT/EP2012/061618 WO2013189516A1 (en) | 2012-06-18 | 2012-06-18 | Method for treating a gd2 positive cancer |
| PCT/EP2012/064970 WO2013189554A1 (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2876529A1 CA2876529A1 (en) | 2013-12-27 |
| CA2876529C true CA2876529C (en) | 2023-09-26 |
Family
ID=46317406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2876529A Active CA2876529C (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10294305B2 (enExample) |
| JP (1) | JP6283665B2 (enExample) |
| KR (1) | KR101927118B1 (enExample) |
| CN (1) | CN104487088A (enExample) |
| AP (1) | AP2014008129A0 (enExample) |
| AU (1) | AU2012383254B2 (enExample) |
| BR (1) | BR112014031806A8 (enExample) |
| CA (1) | CA2876529C (enExample) |
| EA (1) | EA038188B1 (enExample) |
| HK (1) | HK1203375A1 (enExample) |
| IL (1) | IL235696A0 (enExample) |
| MX (1) | MX377157B (enExample) |
| SG (2) | SG11201408487WA (enExample) |
| WO (2) | WO2013189516A1 (enExample) |
| ZA (1) | ZA201407961B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| EA201691055A1 (ru) | 2013-11-21 | 2016-11-30 | Апейрон Биолоджикс Аг | Препараты и способы лечения gd2-положительного рака |
| US9856324B2 (en) * | 2014-06-04 | 2018-01-02 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| US10329323B2 (en) | 2014-07-25 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method for purifying antibodies using PBS |
| WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| JP2020534370A (ja) * | 2017-09-21 | 2020-11-26 | ユーエムセー ユトレヒト ホールディング ベイフェイＵＭＣ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． | 神経芽腫の治療のための抗ｇｄ２抗体 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| WO2020165402A1 (en) | 2019-02-14 | 2020-08-20 | Westfälische Wilhelms-Universität Münster | Gd2-upregulation by ezh2 inhibition in cancer therapy |
| TWI917322B (zh) | 2019-05-17 | 2026-03-11 | 美商癌症預防製藥股份有限公司 | 治療家族性腺瘤性瘜肉症之方法 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| EP4008347B1 (en) * | 2019-08-01 | 2025-04-30 | Mie University | GD2-BINDING MOLECULE |
| WO2021108670A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Utah Research Foundation | Compositions and methods for upregulating hla class i on tumor cells |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| JP2023532753A (ja) | 2020-07-06 | 2023-07-31 | イーユーエスエー ファーマ （ユーケー） リミテッド | Ｇｄ２陽性がんを治療するための方法 |
| WO2023280880A1 (en) * | 2021-07-05 | 2023-01-12 | Trion Research Gmbh | Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| EP4116330A1 (en) * | 2021-07-05 | 2023-01-11 | Trion Research GmbH | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| EP4194471A1 (en) * | 2021-12-10 | 2023-06-14 | Y-Mabs Therapeutics, Inc. | Anti-gd2 administration regimen |
| GB202307103D0 (en) | 2023-05-12 | 2023-06-28 | Prinses Maxima Centrum Voor Kinderoncologie B V | Method for detecting a GD2 positive cancer |
| TW202607019A (zh) * | 2024-06-14 | 2026-02-16 | 美商辛生物科技股份有限公司 | 通過單域抗體對神經退化性疾病之抑制 |
| WO2026125751A1 (en) | 2024-12-13 | 2026-06-18 | Recordati Uk Ltd | Combined treatments of ewing sarcoma with dinutuximab, an anti gd2 antibody and chemotherapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| EP1345968A2 (en) * | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| ATE471946T1 (de) * | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| JP5654986B2 (ja) | 2008-06-30 | 2015-01-14 | モーフオテク・インコーポレーテツド | 抗ｇｄ２抗体並びにそれに関連する方法及び使用 |
| NZ603581A (en) * | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| US8435972B2 (en) * | 2010-09-02 | 2013-05-07 | Emory University | Method for the treatment of central nervous system cancers and compositions related thereto |
| IN2014CN03887A (enExample) | 2011-10-27 | 2015-10-16 | Genmab As | |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| EA201691055A1 (ru) | 2013-11-21 | 2016-11-30 | Апейрон Биолоджикс Аг | Препараты и способы лечения gd2-положительного рака |
| US9840566B2 (en) * | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
-
2012
- 2012-06-18 WO PCT/EP2012/061618 patent/WO2013189516A1/en not_active Ceased
- 2012-07-31 SG SG11201408487WA patent/SG11201408487WA/en unknown
- 2012-07-31 MX MX2014013858A patent/MX377157B/es active IP Right Grant
- 2012-07-31 CA CA2876529A patent/CA2876529C/en active Active
- 2012-07-31 WO PCT/EP2012/064970 patent/WO2013189554A1/en not_active Ceased
- 2012-07-31 SG SG10201610532QA patent/SG10201610532QA/en unknown
- 2012-07-31 BR BR112014031806A patent/BR112014031806A8/pt not_active Application Discontinuation
- 2012-07-31 CN CN201280074061.1A patent/CN104487088A/zh active Pending
- 2012-07-31 JP JP2015517621A patent/JP6283665B2/ja active Active
- 2012-07-31 EA EA201500019A patent/EA038188B1/ru unknown
- 2012-07-31 HK HK15103941.7A patent/HK1203375A1/xx unknown
- 2012-07-31 AP AP2014008129A patent/AP2014008129A0/xx unknown
- 2012-07-31 KR KR1020147033790A patent/KR101927118B1/ko active Active
- 2012-07-31 AU AU2012383254A patent/AU2012383254B2/en active Active
-
2014
- 2014-02-18 US US14/182,776 patent/US10294305B2/en active Active
- 2014-10-31 ZA ZA2014/07961A patent/ZA201407961B/en unknown
- 2014-11-13 IL IL235696A patent/IL235696A0/en unknown
-
2017
- 2017-09-11 US US15/700,538 patent/US11447565B2/en active Active
-
2019
- 2019-04-04 US US16/375,022 patent/US20200055953A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/933,295 patent/US20230340148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013189554A1 (en) | 2013-12-27 |
| US20230340148A1 (en) | 2023-10-26 |
| ZA201407961B (en) | 2015-10-28 |
| CA2876529A1 (en) | 2013-12-27 |
| KR20150030650A (ko) | 2015-03-20 |
| EA038188B1 (ru) | 2021-07-21 |
| MX2014013858A (es) | 2015-02-12 |
| US20180134801A1 (en) | 2018-05-17 |
| AU2012383254A1 (en) | 2014-11-20 |
| US20140170155A1 (en) | 2014-06-19 |
| AU2012383254B2 (en) | 2017-12-14 |
| JP2015521607A (ja) | 2015-07-30 |
| WO2013189516A1 (en) | 2013-12-27 |
| US10294305B2 (en) | 2019-05-21 |
| KR101927118B1 (ko) | 2019-03-12 |
| BR112014031806A2 (pt) | 2017-08-29 |
| SG11201408487WA (en) | 2015-02-27 |
| SG10201610532QA (en) | 2017-02-27 |
| US20200055953A1 (en) | 2020-02-20 |
| JP6283665B2 (ja) | 2018-02-21 |
| EA201500019A1 (ru) | 2015-05-29 |
| BR112014031806A8 (pt) | 2018-01-16 |
| MX377157B (es) | 2025-03-07 |
| IL235696A0 (en) | 2015-01-29 |
| CN104487088A (zh) | 2015-04-01 |
| HK1203375A1 (en) | 2015-10-30 |
| AP2014008129A0 (en) | 2014-12-31 |
| US11447565B2 (en) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230340148A1 (en) | Method for treating a gd2 positive cancer | |
| US9777068B2 (en) | Method for treating a GD2 positive cancer | |
| US11492412B2 (en) | Preparations and methods for treating a GD2 positive cancer | |
| US20260092126A1 (en) | Preparations and methods for treating a gd2 positive cancer | |
| CA2834000A1 (en) | Method for treating a gd2 positive cancer | |
| EP2875827A1 (en) | Preparations and methods for treating a GD2 positive cancer | |
| HK40022685A (en) | Preparations and methods for treating a gd2 positive cancer | |
| HK1223039B (en) | Preparations for treating a gd2 positive cancer | |
| EA043975B1 (ru) | Препараты и способы лечения gd2-положительного рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170412 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250610 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250610 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260609 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260609 |